NCT03876288 - Gastroparesis Outcome Longitudinal Database Enrolled Numerically | Biotech Hunter

Enrollment

3,000

Participants

Timeline

Start Date

January 1, 2013

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2028

Conditions

Gastroparesis

Interventions

DEVICE

GI Neuromodulation

The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.

DRUG

Immunotherapy

The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.

PROCEDURE

Pyloric Therapies

The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.

Trial Locations (1)

40202

RECRUITING

University of Louisville, Louisville